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First discovered… The
existence of T regulatory cells
was first suggested by several
animal models in the 1970s.
Organ-specific autoimmunity
was found to be induced in
specific strains of mice that had
been thymectomized 3 days after
birth but not after thymectomy at
0 or 7 days. It was proposed that
self-reactive T cells emerged
from the thymus immediately
after birth but that there existed
a second, suppressive
population of T cells that did not
emerge until after day 3 of life. It
was not until 1995, however, that
the suppressive cells were
characterized as those CD4+ T
cells that co-expressed the
IL2Rα chain, CD25. Direct
evidence of their existence and
in vitro suppressive function was
then described in 1998.
Do not confuse with...
Suppressor T cells of the 1970s.
Concurrent with the animal
studies mentioned above, the
literature also contained
countless studies that described
subpopulations of T cells with
suppressive activity, which was
attributed to soluble factors
encoded by both immunoglobulin
genes and the I–J locus of the
major histocompatibility complex
(MHC) region. But when an I–J
locus was not found within the
MHC and it was discovered that
the genes encoding the T-cell
receptor were distinct from the
immunoglobulins, suppressor T
cells quickly fell out of favor and
suppressor T cells became a dirty
term. Thus, in the current
literature, CD4+CD25+ suppressor
T cells are typically referred to as
T regulatory cells (Tregs).
Also do not confuse with...
Conventional CD4+ T cells that
express CD25 upon activation —
expression of CD25 does not a
Treg make... Once stimulated,
effector CD4+ T cells express
various surface markers
associated with activation that
are all also expressed on Tregs.
Thus, activated effector CD4+ T
cells are phenotypically similar to
Tregs and can only be
distinguished by a functional
assay. A member of the forkhead
family of transcription factors,
FoxP3, was recently found to be
specific to Tregs and is the best
marker to date for distinguishing
Tregs from effector T cells.
However, the intracellular
localization of FoxP3 limits its use
as a tool to purify Tregs. 
What do they do? CD4+CD25+ T
cells isolated from mice or
humans are able to suppress the
in vitro proliferative response of
conventional CD4+ and CD8+ T
cells. Evidence is also emerging
that suggests Tregs can suppress
the proliferation and function of
other cell types, such as dendritic
cells and B cells. Moreover,
purified CD4+CD25+ T cells are
able to suppress the induction of
autoimmunity in numerous in vivo
models of autoimmunity,
including inflammatory bowel
disease, gastritis and diabetes.
Recent evidence suggests that
Tregs do not prevent the activation
or infiltration of autoreactive T
cells, but they instead prevent
effector functions such as the
secretion of interferon γ.
How do they do it? Although IL-
10 secreted by CD4+CD25+ Tregs
appears to play a protective role
in some models of autoimmunity,
the primary mechanism of
suppression is dependent on cell
contact and results in the
inhibition of IL-2 transcription.
Surprisingly and despite great
effort, the molecules involved in
this cell–cell contact remain
elusive. Recent reports have
suggested that cell-surface
transforming growth factor (TGF)
β, bound to Tregs, is responsible
for their suppressive properties,
but this theory has not generated
widespread support. Other
molecules such as lymphocyte
activation gene 3 (LAG-3) and the
negative costimulatory molecule
CTLA-4 have also been
implicated, but there is no
agreement that they are
responsible for the suppressive
phenotype of Tregs. 
How are they regulated? The
development of CD4+CD25+ Tregs
is regulated by several pathways.
Mice that are deficient in CD25,
the IL-2β receptor CD122 and IL-
2, all involved in IL-2 binding or
signaling, either lack Tregs or have
a severely reduced population.
Mice that are deficient in CD28,
an important co-stimulatory
molecule, lack Tregs as well.
Finally, mice that lack FoxP3 are
also deficient in Tregs. However,
only the ectopic expression of
FoxP3 in CD4+CD25– T cells can
confer the suppressive phenotype
of Tregs, making it the key
regulator of Treg development and
function.
Can we live without them? It
appears that we cannot live for
very long without Tregs. CD25- or
CD122-deficient mice, which, as
previously mentioned, lack Tregs,
develop varying degrees of
lymphoproliferation and
autoimmunity, usually dying
within 12 to 20 weeks of life.
However, the adoptive transfer of
purified CD4+CD25+ T cells during
the neonatal period completely
protects these animals. Mice that
lack Foxp3 suffer from a fatal X-
linked lymphoproliferative
autoimmune syndrome and
typically die at 3 weeks. These
mice, too, can be completely
protected by the transfer of
purified CD4+CD25+ T cells. Also,
humans with mutations in FOXP3
develop a syndrome called IPEX
(immune dysregulation,
polyendocrinopathy, enteropathy,
X-linked syndrome) and, without
bone marrow treatment, patients
die early in life.
Where can I find out more?
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